ReviewTranslational neurodegeneration2015
How to optimize the treatment of early stage Parkinson's disease.
Review in Translational neurodegeneration, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Effect of Caffeine on the Risk and Progression of Parkinson's Disease: A Meta-Analysis.Nutrients · 2020Pooled it
- Consensus-based perspectives on integrating IPX203 into Parkinson's disease management.Journal of neurology · 2026Review
- Modulation of the TGF-β/Smad Signaling Pathway by a Bioactive Oxidized Polygonati Rhizoma Polysaccharide Crosslinked Chitosan Hydrogel as Therapeutic Carrier for Parkinson's Disease Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Effect of Safinamide on Non-Motor Symptoms and Quality of Life in Parkinson's Disease Patients According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose.Brain sciences · 2025Article
- The Role of Astrocytes in Parkinson's Disease : Astrocytes in Parkinson's Disease.Advances in neurobiology · 2024Review
- Real-world Chinese herbal medicine for Parkinson's disease: a hospital-based retrospective analysis of electronic medical records.Frontiers in aging neuroscience · 2024Article
- SmartWear body sensors for neurological and neurosurgical patients: A review of current and future technologies.World neurosurgery: X · 2024Review
- Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial.Neurology and therapy · 2022Article
- Parkinson's disease, treatment choice and survival over time.Clinical parkinsonism & related disorders · 2022Article
- Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD).Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Observational
- Toward clinical digital phenotyping: a timely opportunity to consider purpose, quality, and safety.NPJ digital medicine · 2019Review
- Carbon supported olivine type phosphate framework: a promising electrocatalyst for sensitive detection of dopamine.RSC advances · 2018Article
- Tubulin and Tau: Possible targets for diagnosis of Parkinson's and Alzheimer's diseases.PloS one · 2018Article
- MicroRNA-4639 Is a Regulator of DJ-1 Expression and a Potential Early Diagnostic Marker for Parkinson's Disease.Frontiers in aging neuroscience · 2017Article
- Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.Journal of Parkinson's disease · 2016Article
- Induced pluripotent stem cells and Parkinson's disease: modelling and treatment.Cell proliferation · 2016Review
- In Vitro and in Vivo Neuroprotective Effects of Walnut (Juglandis Semen) in Models of Parkinson's Disease.International journal of molecular sciences · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The approach to early Parkinson's disease denotes the communication of the diagnosis and important decisions, such as when and how to start treatment. Evidence based medicine and guidelines indicate which drugs have robust evidence of efficacy and tolerability in this specific population. However, de-novo patients may show different characteristics and they may be in a different phase of their disease. In this review, we will give an insight into the appropriate time therapy should be started and the actual knowledge about disease modification therapies. Moreover, the drugs indicated for early treatment will be considered and an indication for the use of these drugs will be given with the support of the actual knowledge.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.